遗传成瘾风险评分(GARS)的生物技术发展和物质使用障碍(SUD)中多态性等位基因风险的选择性证据。

K Blum, A Bowirrat, D Baron, L Lott, J V Ponce, R Brewer, D Siwicki, B Boyett, M C Gondre-Lewis, D E Smith, Thanos Panayotis K, S Badgaiyan, M Hauser, L Fried, Roy A, B W Downs, R D Badgaiyan
{"title":"遗传成瘾风险评分(GARS)的生物技术发展和物质使用障碍(SUD)中多态性等位基因风险的选择性证据。","authors":"K Blum,&nbsp;A Bowirrat,&nbsp;D Baron,&nbsp;L Lott,&nbsp;J V Ponce,&nbsp;R Brewer,&nbsp;D Siwicki,&nbsp;B Boyett,&nbsp;M C Gondre-Lewis,&nbsp;D E Smith,&nbsp;Thanos Panayotis K,&nbsp;S Badgaiyan,&nbsp;M Hauser,&nbsp;L Fried,&nbsp;Roy A,&nbsp;B W Downs,&nbsp;R D Badgaiyan","doi":"10.15761/JSIN.1000221","DOIUrl":null,"url":null,"abstract":"<p><p>Research into the neurogenetic basis of addiction identified and characterized by Reward Deficiency Syndrome (RDS) includes all drug and non-drug addictive, obsessive and compulsive behaviors. We are proposing herein that a new model for the prevention and treatment of Substance Use Disorder (SUD) a subset of RDS behaviors, based on objective biologic evidence, should be given serious consideration in the face of a drug epidemic. The development of the Genetic Addiction Risk Score (GARS) followed seminal research in 1990, whereby, Blum's group identified the first genetic association with severe alcoholism published in JAMA. While it is true that no one to date has provided adequate RDS free controls there have been many studies using case -controls whereby SUD has been eliminated. We argue that this deficiency needs to be addressed in the field and if adopted appropriately many spurious results would be eliminated reducing confusion regarding the role of genetics in addiction. However, an estimation, based on these previous literature results provided herein, while not representative of all association studies known to date, this sampling of case- control studies displays significant associations between alcohol and drug risk. In fact, we present a total of <b>110,241</b> cases and <b>122,525</b> controls derived from the current literature. We strongly suggest that while we may take argument concerning many of these so-called controls (e.g. blood donors) it is quite remarkable that there are a plethora of case -control studies indicating selective association of these risk alleles ( measured in GARS) for the most part indicating a hypodopaminergia. The paper presents the detailed methodology of the GARS. Data collection procedures, instrumentation, and the analytical approach used to obtain GARS and subsequent research objectives are described. Can we combat SUD through early genetic risk screening in the addiction field enabling early intervention by the induction of dopamine homeostasis? It is envisaged that GARS type of screening will provide a novel opportunity to help identify causal pathways and associated mechanisms of genetic factors, psychological characteristics, and addictions awaiting additional scientific evidence including a future meta- analysis of all available data -a work in progress.</p>","PeriodicalId":87318,"journal":{"name":"Journal of systems and integrative neuroscience","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891477/pdf/","citationCount":"24","resultStr":"{\"title\":\"Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD).\",\"authors\":\"K Blum,&nbsp;A Bowirrat,&nbsp;D Baron,&nbsp;L Lott,&nbsp;J V Ponce,&nbsp;R Brewer,&nbsp;D Siwicki,&nbsp;B Boyett,&nbsp;M C Gondre-Lewis,&nbsp;D E Smith,&nbsp;Thanos Panayotis K,&nbsp;S Badgaiyan,&nbsp;M Hauser,&nbsp;L Fried,&nbsp;Roy A,&nbsp;B W Downs,&nbsp;R D Badgaiyan\",\"doi\":\"10.15761/JSIN.1000221\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Research into the neurogenetic basis of addiction identified and characterized by Reward Deficiency Syndrome (RDS) includes all drug and non-drug addictive, obsessive and compulsive behaviors. We are proposing herein that a new model for the prevention and treatment of Substance Use Disorder (SUD) a subset of RDS behaviors, based on objective biologic evidence, should be given serious consideration in the face of a drug epidemic. The development of the Genetic Addiction Risk Score (GARS) followed seminal research in 1990, whereby, Blum's group identified the first genetic association with severe alcoholism published in JAMA. While it is true that no one to date has provided adequate RDS free controls there have been many studies using case -controls whereby SUD has been eliminated. We argue that this deficiency needs to be addressed in the field and if adopted appropriately many spurious results would be eliminated reducing confusion regarding the role of genetics in addiction. However, an estimation, based on these previous literature results provided herein, while not representative of all association studies known to date, this sampling of case- control studies displays significant associations between alcohol and drug risk. In fact, we present a total of <b>110,241</b> cases and <b>122,525</b> controls derived from the current literature. We strongly suggest that while we may take argument concerning many of these so-called controls (e.g. blood donors) it is quite remarkable that there are a plethora of case -control studies indicating selective association of these risk alleles ( measured in GARS) for the most part indicating a hypodopaminergia. The paper presents the detailed methodology of the GARS. Data collection procedures, instrumentation, and the analytical approach used to obtain GARS and subsequent research objectives are described. Can we combat SUD through early genetic risk screening in the addiction field enabling early intervention by the induction of dopamine homeostasis? It is envisaged that GARS type of screening will provide a novel opportunity to help identify causal pathways and associated mechanisms of genetic factors, psychological characteristics, and addictions awaiting additional scientific evidence including a future meta- analysis of all available data -a work in progress.</p>\",\"PeriodicalId\":87318,\"journal\":{\"name\":\"Journal of systems and integrative neuroscience\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891477/pdf/\",\"citationCount\":\"24\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of systems and integrative neuroscience\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15761/JSIN.1000221\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2019/12/19 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of systems and integrative neuroscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15761/JSIN.1000221","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/12/19 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 24

摘要

以奖励缺乏综合征(Reward Deficiency Syndrome, RDS)为特征的成瘾的神经遗传学基础研究包括所有药物和非药物成瘾、强迫和强迫行为。我们在此建议,在面对药物流行的情况下,应该认真考虑基于客观生物学证据的物质使用障碍(SUD)行为子集的预防和治疗新模型。遗传成瘾风险评分(GARS)的发展遵循了1990年的开创性研究,布鲁姆的研究小组在《美国医学会杂志》上发表了第一个与严重酒精中毒有关的基因。虽然迄今为止没有人提供足够的无RDS对照,但已经有许多研究使用病例对照,其中SUD已被消除。我们认为这一缺陷需要在该领域得到解决,如果适当采用,许多虚假的结果将被消除,减少关于遗传在成瘾中的作用的混乱。然而,基于本文提供的这些先前文献结果的估计,虽然不能代表迄今已知的所有关联研究,但这一病例对照研究的抽样显示了酒精和药物风险之间的显著关联。事实上,我们从现有文献中获得了110,241例病例和122,525例对照。我们强烈建议,尽管我们可能会对这些所谓的对照(例如献血)有争议,但值得注意的是,有大量的病例对照研究表明,这些风险等位基因(在GARS中测量)的选择性关联在很大程度上表明了多巴胺能低下。本文介绍了GARS的具体方法。数据收集程序,仪器和分析方法用于获得GARS和随后的研究目标进行了描述。我们能否通过成瘾领域的早期遗传风险筛查来对抗SUD,从而通过诱导多巴胺稳态进行早期干预?据设想,GARS类型的筛查将提供一个新的机会,以帮助确定遗传因素,心理特征和成瘾的因果途径和相关机制,等待更多的科学证据,包括未来对所有可用数据的元分析-这项工作正在进行中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD).

Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD).

Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD).

Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD).

Research into the neurogenetic basis of addiction identified and characterized by Reward Deficiency Syndrome (RDS) includes all drug and non-drug addictive, obsessive and compulsive behaviors. We are proposing herein that a new model for the prevention and treatment of Substance Use Disorder (SUD) a subset of RDS behaviors, based on objective biologic evidence, should be given serious consideration in the face of a drug epidemic. The development of the Genetic Addiction Risk Score (GARS) followed seminal research in 1990, whereby, Blum's group identified the first genetic association with severe alcoholism published in JAMA. While it is true that no one to date has provided adequate RDS free controls there have been many studies using case -controls whereby SUD has been eliminated. We argue that this deficiency needs to be addressed in the field and if adopted appropriately many spurious results would be eliminated reducing confusion regarding the role of genetics in addiction. However, an estimation, based on these previous literature results provided herein, while not representative of all association studies known to date, this sampling of case- control studies displays significant associations between alcohol and drug risk. In fact, we present a total of 110,241 cases and 122,525 controls derived from the current literature. We strongly suggest that while we may take argument concerning many of these so-called controls (e.g. blood donors) it is quite remarkable that there are a plethora of case -control studies indicating selective association of these risk alleles ( measured in GARS) for the most part indicating a hypodopaminergia. The paper presents the detailed methodology of the GARS. Data collection procedures, instrumentation, and the analytical approach used to obtain GARS and subsequent research objectives are described. Can we combat SUD through early genetic risk screening in the addiction field enabling early intervention by the induction of dopamine homeostasis? It is envisaged that GARS type of screening will provide a novel opportunity to help identify causal pathways and associated mechanisms of genetic factors, psychological characteristics, and addictions awaiting additional scientific evidence including a future meta- analysis of all available data -a work in progress.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信